Subhashis Banerjee Sells 8,222 Shares of Artiva Biotherapeutics (NASDAQ:ARTV) Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) insider Subhashis Banerjee sold 8,222 shares of the firm’s stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $12.01, for a total transaction of $98,746.22. Following the transaction, the insider directly owned 142,047 shares of the company’s stock, valued at $1,705,984.47. The trade was a 5.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Subhashis Banerjee also recently made the following trade(s):

• On Tuesday, August 18th, Subhashis Banerjee sold 429 shares of Artiva Biotherapeutics stock. The stock was sold at an average price of $12.00, for a total transaction of $5,148.00.

Artiva Biotherapeutics Stock Up 1.9%

ARTV traded up $0.21 during midday trading on Monday, reaching $11.30. 249,843 shares of the company’s stock were exchanged, compared to its average volume of 315,106. Artiva Biotherapeutics, Inc. has a one year low of $2.22 and a one year high of $14.53. The business has a 50-day simple moving average of $10.42 and a two-hundred day simple moving average of $8.58.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its earnings results on Thursday, August 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.63). Equities analysts predict that Artiva Biotherapeutics, Inc. will post -2.62 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on ARTV shares. Needham & Company LLC reissued a “buy” rating and set a $41.00 price target on shares of Artiva Biotherapeutics in a report on Monday, June 8th. Wedbush boosted their target price on Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a report on Monday, May 11th. HC Wainwright raised their price target on Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a report on Friday, May 8th. Cantor Fitzgerald restated an “overweight” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, May 26th. Finally, Wall Street Zen raised shares of Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $39.00.

Institutional Investors Weigh In On Artiva Biotherapeutics

A number of institutional investors and hedge funds have recently modified their holdings of ARTV. Marshall Wace LLP acquired a new position in Artiva Biotherapeutics in the second quarter valued at about $79,000. Qube Research & Technologies Ltd acquired a new stake in shares of Artiva Biotherapeutics in the 2nd quarter valued at approximately $58,000. Jane Street Group LLC bought a new position in Artiva Biotherapeutics during the 2nd quarter worth approximately $67,000. Bridgeway Capital Management LLC acquired a new position in Artiva Biotherapeutics during the second quarter valued at approximately $53,000. Finally, BNP Paribas Financial Markets raised its holdings in Artiva Biotherapeutics by 14,463.5% in the third quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock worth $340,000 after purchasing an additional 117,733 shares during the period.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.